Swayed by IBM's Watson boasts, McKinsey predicted a 30–50 percent productivity improvement for nurses, a 5–9 percent reduction in health care costs, and health care savings in developed countries equal to up to 2 percent of GDP. The Wall Street Journal published a cautionary article in 2017, and soon others were questioning the hype. A 2019 article in IEEE Spectrum concluded that Watson had "overpromised and underdelivered." Soon afterward, IBM pulled Watson from drug discovery, and media enthusiasm waned as bad news about A.I. health care accumulated. For example, a 2020 Mayo Clinic and Harvard survey of clinical staff who were using A.I.-based clinical decision support to improve glycemic control in patients with diabetes gave the program a median score of 11 on a scale of 0 to 100, with only 14 percent saying that they would recommend the system to other clinics.